A new breast cancer drug has received FDA approval after clinical trials showed it can reduce the risk of disease progression by nearly 40 per cent. With Inluriyo - an oral estrogen receptor antagonist, this breakthrough offers hope for patients by slowing cancer advancement and improving treatment outcomes.